Compare CRNX & BMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNX | BMI |
|---|---|---|
| Founded | 2008 | 1905 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.3B |
| IPO Year | 2018 | 1994 |
| Metric | CRNX | BMI |
|---|---|---|
| Price | $83.86 | $150.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 11 |
| Target Price | $76.75 | ★ $170.13 |
| AVG Volume (30 Days) | ★ 6.0M | 435.3K |
| Earning Date | 05-07-2026 | 04-17-2026 |
| Dividend Yield | N/A | ★ 1.36% |
| EPS Growth | N/A | ★ 13.24 |
| EPS | N/A | ★ 0.93 |
| Revenue | ★ $1,039,000.00 | N/A |
| Revenue This Year | $720.10 | $5.97 |
| Revenue Next Year | $184.67 | $7.17 |
| P/E Ratio | ★ N/A | $161.18 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.83 | $112.09 |
| 52 Week High | $84.00 | $204.00 |
| Indicator | CRNX | BMI |
|---|---|---|
| Relative Strength Index (RSI) | 92.91 | 62.10 |
| Support Level | $41.42 | $142.68 |
| Resistance Level | N/A | $153.63 |
| Average True Range (ATR) | 0.85 | 5.47 |
| MACD | 2.82 | 0.03 |
| Stochastic Oscillator | 99.68 | 71.31 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Badger Meter is a provider of water management solutions. The company's solutions encompass measurement and control hardware, connectivity and communication, data visualization and software. Badger Meter has globalised operations, with the vast majority of revenue derived from the USA. The company is an innovator in flow measurement, water quality and control products, serving water utilities, municipalities and commercial and industrial customers world-wide.